Collectively, these findings indicate that ES-62 primarily acts directly to normalise the CIA-associated gut dysbiosis that both triggers mucosal inflammation and initiates the mesenteric lymph node (MLN) IL-17 responses that drive autoimmunity, rather than indirectly modulating the dysbiosis and gut pathology arising from the systemic inflammation that results from the CIA-immunisation protocol. Here, IL17A is linked to Autoimmunity.